United States:
Podcast: SaMD Series: What Should Life Sciences Companies Know?
21 August 2018
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
To print this article, all you need is to be registered or login on Mondaq.com.
Software as a Medical Device – also referred to as SaMD
– is one of the fastest growing innovations in the medical
device industry. As with any technology that experiences rapid
adoption, challenges related to IP protection often follow. In this
series, we're taking a closer look at IP considerations that
SaMD developers should be aware of.
In this podcast, Finnegan attorneys Eric Raciti and Cory Bell
explore nuances of IP law that life sciences companies should
consider when developing an SaMD.
To listen to the podcast, please click Here
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
Healthcare Policy Developments To Watch In 2024
Crowell & Moring LLP
The ever-changing healthcare policy landscape will witness at the federal level regulatory changes driven by the need to transform healthcare delivery, quality and innovation.
The FDA And The Future Of AI Oversight
Manatt, Phelps & Phillips LLP
In January 2024, the U.S. Government Accountability Office (GAO) issued a report highlighting current obstacles to the U.S. Food and Drug Administration's (FDA) timely and effective regulation...